Tocilizumab patent expiry?

Patent expiry for tocilizumab is not a single date. It depends on the country and on which patent family you’re looking at (composition of matter, manufacturing process, use, formulation, etc.), plus regulatory data protection in some regions.

Key points:
- Tocilizumab’s core patent families cover the antibody itself and related technologies, and those patent protections have ended or are ending at different times across jurisdictions.
- Many major markets have seen the primary composition-of-matter patents expire in the 2010s or early 2020s, but there can still be active patents in specific territories, as well as patent term extensions and data protection that affect market exclusivity.
- Even after patent expiry, regulatory data protection (especially for biologics) and other patents (process, formulation, method of use) can influence when biosimilars can enter a market.

If you want precise expiry dates, please tell me:
- The country or region you’re interested in (e.g., US, EU, UK, Japan, India, etc.).
- Whether you want a quick status (policy: core composition patents expired/did not expire) or a detailed list of active patents and their expected expiry dates.

I can then give you jurisdiction-specific info or guide you to reliable patent databases (USPTO, Espacenet, WIPO PATENTSCOPE, Google Patents) to verify current statuses.